Abstract | INTRODUCTION: AREAS COVERED: This review examines the literature for the pharmacology, pharmacokinetics, clinical efficacy and safety of voglibose in patients with T2DM. Particular focus is on its efficacy in preventing T2DM in individuals with IGT and its efficacy as add-on therapy or in combination with other oral antidiabetic agents in patients with T2DM. EXPERT OPINION: As the relationship between glucose levels and cardiovascular risk extends below the diabetic threshold, postprandial hyperglycemia is recognized as a key therapeutic target in the treatment of T2DM. Strategies to prevent the progression of IGT to overt T2DM have enormous potential to reduce the individual and societal burden of disease. Voglibose is the first oral antidiabetic agent to gain approval in Japan for this indication.
|
Authors | Kohei Kaku |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 15
Issue 8
Pg. 1181-90
(Jun 2014)
ISSN: 1744-7666 [Electronic] England |
PMID | 24798092
(Publication Type: Journal Article, Review)
|
Chemical References |
- Hypoglycemic Agents
- Insulin
- Inositol
- voglibose
|
Topics |
- Atherosclerosis
(prevention & control)
- Diabetes Mellitus, Type 2
(complications, drug therapy, metabolism)
- Diabetic Angiopathies
(prevention & control)
- Drug Therapy, Combination
- Glucose Intolerance
- Humans
- Hypoglycemic Agents
(pharmacology, therapeutic use)
- Inositol
(analogs & derivatives, pharmacology, therapeutic use)
- Insulin
(therapeutic use)
- Practice Guidelines as Topic
- Treatment Outcome
|